基本信息
浏览量:114
职业迁徙
个人简介
My research has been focused on prostate and breast cancer genomics, proteomics and cancer biology. My goal is to understand the complex molecular events involved in cancer, identify early diagnostic markers, valuable therapeutic targets and decipher signaling events involved in cancer progression. Discovery of fusion genes involved in cancer using Next generation sequencing platforms that would provide a new direction to understand the pathogenesis of the cancer, as well as diagnosis and therapy.
Dr. Ateeq’s group is primarily interested in exploring the genetic and epigenetic changes that initiate cancer and its progression by employing novel strategies and approaches. Her overarching goal is to explore the molecular events that drive cancer and facilitate the process of acquiring resistance towards chemotherapeutic drugs, in hopes that these discoveries can lead to the development of more effective therapies against specific causative pathways or alterations. Since cancer is a heterogenous disease, which is known to evolve from diverse genetic alterations such as mutations, gene fusions/rearrangements, amplifications/deletions, and other aberrations that perturb gene expression. Therefore, her group is putting efforts in exploring the comprehensive mutational landscape of Indian prostate cancer patients representing the entire disease spectrum (indolent localized to aggressive metastatic disease), understanding the functional significance of the newly identified mutation(s) and in identification of actionable alterations.
Considering racial disparities and clinical-treatment options available in India, exploring mutational profiles of these patient is critical for understanding the disease pathobiology and in redefining therapeutic targets. Thus, the major focus of Molecular Oncology Laboratory is:
Integrative sequencing for comprehensive identification of clinically significant alterations in Indian prostate cancer patients.
Genome wide screen of frequently mutated and hotspot regions associated with prostate cancer risk.
Characterize functional relevance of the genetic or epigenetic alterations by employing molecular and cellular approaches.
Understand the molecular mechanisms involved in the emergence of aggressive prostate cancer subtype to overcome anti-androgen or drug resistance.
Develop prostate cancer patient-derived organoids from biopsies and utilize them for genomic characterization and potential drug screen.
Develop tumor cell-free DNA or exosome-based diagnostics panel for clinically-relevant aberrations for screening advanced stage prostate cancer patients.
Dr. Ateeq’s group is primarily interested in exploring the genetic and epigenetic changes that initiate cancer and its progression by employing novel strategies and approaches. Her overarching goal is to explore the molecular events that drive cancer and facilitate the process of acquiring resistance towards chemotherapeutic drugs, in hopes that these discoveries can lead to the development of more effective therapies against specific causative pathways or alterations. Since cancer is a heterogenous disease, which is known to evolve from diverse genetic alterations such as mutations, gene fusions/rearrangements, amplifications/deletions, and other aberrations that perturb gene expression. Therefore, her group is putting efforts in exploring the comprehensive mutational landscape of Indian prostate cancer patients representing the entire disease spectrum (indolent localized to aggressive metastatic disease), understanding the functional significance of the newly identified mutation(s) and in identification of actionable alterations.
Considering racial disparities and clinical-treatment options available in India, exploring mutational profiles of these patient is critical for understanding the disease pathobiology and in redefining therapeutic targets. Thus, the major focus of Molecular Oncology Laboratory is:
Integrative sequencing for comprehensive identification of clinically significant alterations in Indian prostate cancer patients.
Genome wide screen of frequently mutated and hotspot regions associated with prostate cancer risk.
Characterize functional relevance of the genetic or epigenetic alterations by employing molecular and cellular approaches.
Understand the molecular mechanisms involved in the emergence of aggressive prostate cancer subtype to overcome anti-androgen or drug resistance.
Develop prostate cancer patient-derived organoids from biopsies and utilize them for genomic characterization and potential drug screen.
Develop tumor cell-free DNA or exosome-based diagnostics panel for clinically-relevant aberrations for screening advanced stage prostate cancer patients.
研究兴趣
论文共 122 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nishat Manzar,Umar Khalid Khan, Ayush Goel,Shannon Carskadon, Nilesh Gupta,Nallasivam Palanisamy,Bushra Ateeq
ISCIENCEno. 3 (2024): 108794-108794
crossref(2023)
Shivansh Nigam,Umar Khalid Khan, Ayush Praveen, Akshay Shendre,Shannon Carskadon, Abhimanyu Kapoor, Anjali Tewari,Abhijit Chandra,Nallasivam Palanisamy,Bushra Ateeq
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Anjali Yadav,Tanay Biswas, Ayush Praveen,Promit Ganguly, Ankita Bhattacharyya,Ayushi Verma,Dipak Datta,Bushra Ateeq
CANCER RESEARCH COMMUNICATIONSno. 10 (2023): 2044-2061
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn